Barclays lowered the firm’s price target on Tarsus Pharmaceuticals (TARS) to $60 from $62 and keeps an Overweight rating on the shares following the Q4 report. The firm says Xdemvy 2025 sales growth will vary by quarter.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARS:
- Tarsus Pharmaceuticals Reports Strong 2024 Financial Results
- Tarsus Pharmaceuticals price target lowered to $70 from $75 at BofA
- Tarsus Pharmaceuticals: Strong Buy Rating Driven by Impressive Financial Performance and Strategic Growth Positioning
- Tarsus Pharmaceuticals reports Q4 EPS (60c), consensus (82c)
- Strong Growth Prospects and Market Expansion Drive Buy Rating for Tarsus Pharmaceuticals